Tandem Diabetes Care, Inc. (TNDM) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: 272.05
P/FCF
↑
N/A
—
5yr avg: 252.83
30Y Low110.3·High176.2
P/B Ratio
↓
7.82
↓-27% vs avg
5yr avg: 10.71
30Y Low5.1·High22.4
ROE
↓
-97.9%
↑-135% vs avg
5yr avg: -41.6%
30Y Low-290%·High4%
Debt/EBITDA
N/A
—
5yr avg: 8.62
30Y Low8.6·High8.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TNDM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tandem Diabetes Care, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.5B | $2.4B | $1.9B | $2.9B | $9.7B | $5.8B | $3.5B | $1.8B | $13M | $66M |
| Enterprise Value | $1.6B | $1.8B | $2.8B | $2.3B | $3.1B | $9.9B | $6.0B | $3.5B | $1.8B | $76M | $100M |
| P/E Ratio → | -5.93 | — | — | — | — | 627.17 | — | — | — | — | — |
| P/S Ratio | 1.22 | 1.46 | 2.51 | 2.57 | 3.60 | 13.78 | 11.70 | 9.63 | 9.94 | 0.12 | 0.78 |
| P/B Ratio | 7.82 | 9.53 | 8.96 | 6.13 | 6.55 | 22.36 | 15.93 | 17.89 | 13.92 | — | — |
| P/FCF | — | — | 472.08 | — | 176.17 | 110.26 | — | 155.94 | — | — | — |
| P/OCF | — | — | 97.32 | — | 57.14 | 86.98 | 236.55 | 83.22 | — | — | — |
P/E links to full P/E history page with 30-year chart
TNDM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.81 | 2.94 | 3.05 | 3.91 | 14.13 | 11.97 | 9.54 | 9.71 | 0.71 | 1.19 |
| EV / EBITDA | — | — | — | — | — | 272.05 | 2393.44 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 491.21 | — | — | — | — | — |
| EV / FCF | — | — | 553.04 | — | 191.28 | 113.03 | — | 154.56 | — | — | — |
TNDM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Tandem Diabetes Care, Inc. earns an operating margin of -7.7%. Operating margins have expanded from -31.2% to -7.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -97.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.3% | 52.3% | 52.1% | 49.2% | 51.5% | 53.5% | 52.2% | 53.6% | 48.9% | 41.0% | 28.0% |
| Operating Margin | -7.7% | -7.7% | -10.5% | -31.2% | -11.6% | 3.2% | -1.6% | -4.6% | -24.3% | -58.5% | -92.6% |
| Net Profit Margin | -20.2% | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | -6.9% | -6.8% | -66.7% | -67.9% | -99.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -97.9% | -97.9% | -33.3% | -59.1% | -21.7% | 3.9% | -12.3% | -15.2% | -240.1% | — | -290.0% |
| ROA | -22.1% | -22.1% | -10.0% | -22.2% | -9.7% | 1.9% | -6.6% | -9.3% | -81.3% | -70.3% | -70.3% |
| ROIC | -10.0% | -10.0% | -11.1% | -25.8% | -10.2% | 2.9% | -1.8% | -9.9% | -54.4% | -152.2% | -149.3% |
| ROCE | -11.5% | -11.5% | -13.4% | -28.4% | -11.2% | 3.3% | -1.9% | -9.1% | -44.8% | -89.8% | -87.0% |
TNDM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $354M ($444M total debt minus $91M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.86 | 2.86 | 1.80 | 1.33 | 0.95 | 0.73 | 0.62 | 0.10 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 8.62 | 91.55 | — | — | — | — |
| Net Debt / Equity | — | 2.28 | 1.54 | 1.14 | 0.56 | 0.56 | 0.37 | -0.16 | -0.32 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | 6.67 | 53.61 | — | — | — | — |
| Debt / FCF | — | — | 80.96 | — | 15.11 | 2.77 | — | -1.38 | — | — | — |
| Interest Coverage | -24.33 | -24.33 | -13.39 | -21.47 | -14.26 | 3.35 | -1.83 | -314.44 | -15.16 | -5.44 | -13.62 |
TNDM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Tandem Diabetes Care, Inc.'s current ratio of 2.55x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.02x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.83x to 2.55x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | 2.55 | 2.93 | 3.83 | 5.14 | 6.15 | 6.14 | 2.78 | 2.83 | 1.78 | 2.93 |
| Quick Ratio | 2.02 | 2.02 | 2.33 | 3.02 | 4.47 | 5.63 | 5.52 | 2.28 | 2.53 | 1.03 | 2.25 |
| Cash Ratio | 1.21 | 1.21 | 1.77 | 2.40 | 3.73 | 4.73 | 4.67 | 1.78 | 1.95 | 0.39 | 1.70 |
| Asset Turnover | — | 1.15 | 0.97 | 0.78 | 0.76 | 0.78 | 0.70 | 1.11 | 0.89 | 1.13 | 0.75 |
| Inventory Turnover | 3.76 | 3.76 | 3.01 | 2.41 | 3.49 | 4.76 | 3.74 | 3.43 | 4.73 | 2.35 | 2.86 |
| Days Sales Outstanding | — | 59.53 | 44.48 | 51.53 | 52.26 | 57.51 | 60.14 | 46.93 | 69.86 | 70.53 | 48.40 |
TNDM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tandem Diabetes Care, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 0.2% | — | — | — | — | — |
| FCF Yield | — | — | 0.2% | — | 0.6% | 0.9% | — | 0.6% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $67M | $65M | $65M | $64M | $64M | $61M | $59M | $48M | $6M | $3M |
Peer Comparison
Compare TNDM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TNDMYou | $1B | -5.9 | — | — | 52.3% | -7.7% | -97.9% | -10.0% | — |
 PODD | $11B | 43.4 | 18.7 | 28.1 | 71.6% | 17.5% | 18.1% | 20.1% | 1.8 |
 DXCM | $23B | 28.9 | 20.4 | 21.6 | 60.0% | 19.6% | 34.5% | 18.7% | 1.2 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 MDT | $99B | 21.5 | 14.3 | 19.2 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 NVO | $203B | 12.7 | 9.4 | 44.7 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 SANA | $955M | -3.1 | — | — | — | — | -99.2% | -86.1% | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ABT | $150B | 11.3 | 15.7 | 23.6 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See TNDM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNDM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNDM vs PODD
Side-by-side business, growth, and profitability comparison vs Insulet Corporation.
Start ComparisonTNDM — Frequently Asked Questions
Quick answers to the most common questions about buying TNDM stock.
What is Tandem Diabetes Care, Inc.'s P/E ratio?
Tandem Diabetes Care, Inc.'s current P/E ratio is -5.9x. This places it at the 50th percentile of its historical range.
What is Tandem Diabetes Care, Inc.'s ROE?
Tandem Diabetes Care, Inc.'s return on equity (ROE) is -97.9%. The historical average is -89.3%.
Is TNDM stock overvalued?
Based on historical data, Tandem Diabetes Care, Inc. is trading at a P/E of -5.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Tandem Diabetes Care, Inc.'s profit margins?
Tandem Diabetes Care, Inc. has 52.3% gross margin and -7.7% operating margin.